# CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer

> **NCT03699319** · PHASE1,PHASE2 · COMPLETED · sponsor: **David Bajor, MD** · enrollment: 49 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** CPI 613
- **DRUG:** Oxaliplatin
- **DRUG:** Irinotecan
- **DRUG:** 5-flurouracil
- **DRUG:** Folinic acid

## Key facts

- **NCT ID:** NCT03699319
- **Lead sponsor:** David Bajor, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-07
- **Primary completion:** 2024-09-23
- **Final completion:** 2024-09-23
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2025-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03699319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03699319, "CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03699319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*